First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
Related Posts
Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S,[...]
Teysir J, Lloyd MR, Alkassis S, Callahan RD, Fairley R, Wander SA, Bardia A, Jhaveri KL. After a CDK4/6 Inhibitor: State of the Art in[...]
Britten K, Bardia A, McAndrew N. Role of immunotherapy in early breast cancer: past, present, and future. Target Oncol. 2025 Jun 20. doi: 10.1007/s11523-025-01157-1. Epub[...]